164 related articles for article (PubMed ID: 36913134)
1. Whether the Subacute MPTP-Treated Mouse is as Suitable as a Classic Model of Parkinsonism.
Qi Y; Zhang Z; Li Y; Zhao G; Huang J; Zhang Y; Xue J; Tang X
Neuromolecular Med; 2023 Sep; 25(3):360-374. PubMed ID: 36913134
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Necroptosis Inhibitor Improving Dopaminergic Neuronal Loss after MPTP Exposure in Mice.
Oliveira SR; Dionísio PA; Gaspar MM; Ferreira MBT; Rodrigues CAB; Pereira RG; Estevão MS; Perry MJ; Moreira R; Afonso CAM; Amaral JD; Rodrigues CMP
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069782
[TBL] [Abstract][Full Text] [Related]
3. Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Zhang QS; Heng Y; Mou Z; Huang JY; Yuan YH; Chen NH
Acta Pharmacol Sin; 2017 Oct; 38(10):1317-1328. PubMed ID: 28649132
[TBL] [Abstract][Full Text] [Related]
4. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
5. The Neuroprotective Effects of GPR4 Inhibition through the Attenuation of Caspase Mediated Apoptotic Cell Death in an MPTP Induced Mouse Model of Parkinson's Disease.
Haque ME; Azam S; Akther M; Cho DY; Kim IS; Choi DK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925146
[TBL] [Abstract][Full Text] [Related]
6. Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson's Disease.
Massaquoi MS; Liguore WA; Churchill MJ; Moore C; Melrose HL; Meshul CK
Neuroscience; 2020 May; 433():53-71. PubMed ID: 32142862
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
Pariyar R; Bastola T; Lee DH; Seo J
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216503
[TBL] [Abstract][Full Text] [Related]
8. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Petroske E; Meredith GE; Callen S; Totterdell S; Lau YS
Neuroscience; 2001; 106(3):589-601. PubMed ID: 11591459
[TBL] [Abstract][Full Text] [Related]
9. Modeling of the Progressive Degradation of the Nigrostriatal Dopaminergic System in Mice to Study the Mechanisms of Neurodegeneration and Neuroplasticity in Parkinson's Disease.
Kolacheva A; Bannikova A; Pavlova E; Bogdanov V; Ugrumov M
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614126
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
[TBL] [Abstract][Full Text] [Related]
11. miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease.
Hu YB; Zhang YF; Wang H; Ren RJ; Cui HL; Huang WY; Cheng Q; Chen HZ; Wang G
Cell Death Dis; 2019 Aug; 10(8):589. PubMed ID: 31383850
[TBL] [Abstract][Full Text] [Related]
12. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
13. Analysis of m6A modification regulators in the substantia nigra and striatum of MPTP-induced Parkinson's disease mice.
Yu Z; Huang L; Xia Y; Cheng S; Yang C; Chen C; Zou Z; Wang X; Tian X; Jiang X; Zhou L
Neurosci Lett; 2022 Nov; 791():136907. PubMed ID: 36209975
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease.
Haga H; Matsuo K; Yabuki Y; Zhang C; Han F; Fukunaga K
Neurochem Int; 2019 Oct; 129():104492. PubMed ID: 31229554
[TBL] [Abstract][Full Text] [Related]
15. Tonic Activation of NR2D-Containing NMDARs Exacerbates Dopaminergic Neuronal Loss in MPTP-Injected Parkinsonian Mice.
Sharma R; Neupane C; Pham TL; Lee M; Lee S; Lee SY; Nam MH; Kim CS; Park JB
J Neurosci; 2023 Nov; 43(46):7730-7744. PubMed ID: 37726169
[TBL] [Abstract][Full Text] [Related]
16. Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model.
Gu PS; Moon M; Choi JG; Oh MS
J Nutr Biochem; 2017 Jan; 39():15-21. PubMed ID: 27741433
[TBL] [Abstract][Full Text] [Related]
17. [Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].
Wang YS; Zhou JP; Wei ZF; Tian QY; Zhou HX; Zhang YX
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1199-202, 1205. PubMed ID: 17715026
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
Kanagaraj N; Beiping H; Dheen ST; Tay SS
Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
[TBL] [Abstract][Full Text] [Related]
19. Necrosulfonamide exerts neuroprotective effect by inhibiting necroptosis, neuroinflammation, and α-synuclein oligomerization in a subacute MPTP mouse model of Parkinson's disease.
Leem YH; Kim DY; Park JE; Kim HS
Sci Rep; 2023 May; 13(1):8783. PubMed ID: 37258791
[TBL] [Abstract][Full Text] [Related]
20. Brain Selective Estrogen Treatment Protects Dopaminergic Neurons and Preserves Behavioral Function in MPTP-induced Mouse Model of Parkinson's Disease.
Thadathil N; Xiao J; Hori R; Alway SE; Khan MM
J Neuroimmune Pharmacol; 2021 Sep; 16(3):667-678. PubMed ID: 33221984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
